


Product Name : BBO-8520
Cat. No. : PC-22123
CAS No. : 2893809-51-1
Molecular Formula : C₃₅H₃₃F₆N₇O₂S
Molecular Weight : 729.75
Target : Ras
Solubility : 10 mM in DMSO



CAS: 2893809-51-1

Biological Activity

BBO-8520 (BBO8520) is a potent, selective and covalent inhibitor of **KRAS G12C** (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding.

BBO-8520 binds in the switch II pocket and covalently modifies both the (ON) and (OFF) forms of KRASG12C independently of any other partner proteins.

BBO-8520 inhibits KRASG12C (ON) by locking the GTP-bound protein in state 1.

BBO-8520 displays highly significant binding to KRAS G12C in a global cysteine proteome analysis and is 100x more selective for KRASG12C than for WT KRAS and other mutant isoforms, with no measurable activity against N- or H-RAS.

BBO-8520 has sub-nanomolar potency against KRASG12C mutant cell lines.

BBO-8520 rapidly and completely blocks the RAS-RAF1 interaction in effector binding assays, at least 30x more potent than sotorasib and adagrasib at preventing outgrowth in long-term clonogenic assays.

BBO-8520 (10 mg/kg, daily dosing, oral) causes significant tumor volume regression in the KrasG12C-p53 driven GEMM model, exhibits in vivo target engagement and pERK inhibition in the MIA PaCa-2 and H358 KRASG12C mutant tumor models.

References

Anna E. Maciag, et al. **Cancer Res** (2024) 84 (7_Supplement): ND07.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com